Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell LymphomasByJose Sandoval Sus, MDAugust 8th 2025Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Identifying Limitations to CAR T-Cell Therapies in Large B-Cell LymphomaByJose Sandoval Sus, MDAugust 6th 2025Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.